211 related articles for article (PubMed ID: 32901776)
1. Cutaneous manifestations in neurofibromatosis type 1.
Miraglia E; Moliterni E; Iacovino C; Roberti V; Laghi A; Moramarco A; Giustini S
Clin Ter; 2020; 171(5):e371-e377. PubMed ID: 32901776
[TBL] [Abstract][Full Text] [Related]
2. An Update on Neurofibromatosis Type 1: Not Just Café-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer.
Hernández-Martín A; Duat-Rodríguez A
Actas Dermosifiliogr; 2016; 107(6):465-73. PubMed ID: 26956402
[TBL] [Abstract][Full Text] [Related]
3. Nevus anemicus in neurofibromatosis type 1: a potential new diagnostic criterion.
Marque M; Roubertie A; Jaussent A; Carneiro M; Meunier L; Guillot B; Pinson L; Pinson S; Bessis D
J Am Acad Dermatol; 2013 Nov; 69(5):768-775. PubMed ID: 23972508
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Findings in Neurofibromatosis Type 1.
Ozarslan B; Russo T; Argenziano G; Santoro C; Piccolo V
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530415
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis Type 1: Diagnostic Timelines in Children.
García-Martínez FJ; Hernández-Martín A
Actas Dermosifiliogr; 2023 Mar; 114(3):187-193. PubMed ID: 36370836
[TBL] [Abstract][Full Text] [Related]
6. An Update on Neurofibromatosis Type 1: Not Just Café-au-Lait Spots, Freckling, and Neurofibromas. An Update. Part I. Dermatological Clinical Criteria Diagnostic of the Disease.
Hernández-Martín A; Duat-Rodríguez A
Actas Dermosifiliogr; 2016; 107(6):454-64. PubMed ID: 26979265
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous and Systemic Findings in Mosaic Neurofibromatosis Type 1.
Vázquez-Osorio I; Duat-Rodríguez A; García-Martínez FJ; Torrelo A; Noguera-Morel L; Hernández-Martín A
Pediatr Dermatol; 2017 May; 34(3):271-276. PubMed ID: 28318056
[TBL] [Abstract][Full Text] [Related]
8. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience.
Kokkinou E; Roka K; Alexopoulos A; Tsina E; Nikas I; Krallis P; Thanopoulou I; Nasi L; Makrygianni E; Tsoutsou E; Kosma K; Tsipi M; Tzetis M; Frysira H; Kattamis A; Pons R
Postgrad Med; 2019 Sep; 131(7):445-452. PubMed ID: 31443616
[TBL] [Abstract][Full Text] [Related]
9. [Neurofibromas in Type I Neurofibromatosis. Description of a clinical case and literature review].
Del Puerto C; Aspee M; Downey C
Andes Pediatr; 2022 Oct; 93(5):741-748. PubMed ID: 37906895
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Manifestations not Considered Diagnostic Criteria for Neurofibromatosis Type 1. A Case-Control Study.
García-Martínez FJ; Duat-Rodríguez A; Andrés Esteban E; Torrelo A; Noguera Morel L; Hernández-Martín A
Actas Dermosifiliogr; 2022; 113(10):T923-T929. PubMed ID: 36162491
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Manifestations not Considered Diagnostic Criteria for Neurofibromatosis Type 1. A Case-Control Study.
García-Martínez FJ; Duat-Rodríguez A; Andrés Esteban E; Torrelo A; Noguera Morel L; Hernández-Martín A
Actas Dermosifiliogr; 2022; 113(10):923-929. PubMed ID: 35636506
[TBL] [Abstract][Full Text] [Related]
12. Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature.
Bernier A; Larbrisseau A; Perreault S
Pediatr Neurol; 2016 Jul; 60():24-29.e1. PubMed ID: 27212418
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis type 1.
Anderson JL; Gutmann DH
Handb Clin Neurol; 2015; 132():75-86. PubMed ID: 26564071
[TBL] [Abstract][Full Text] [Related]
14. Studies on café au lait spots in neurofibromatosis and pigmented macules of nevus spilus.
Takahasi M
Tohoku J Exp Med; 1976 Mar; 118(3):255-73. PubMed ID: 817416
[TBL] [Abstract][Full Text] [Related]
15. Ophthalmological manifestations in segmental neurofibromatosis type 1.
Ruggieri M; Pavone P; Polizzi A; Di Pietro M; Scuderi A; Gabriele A; Spalice A; Iannetti P
Br J Ophthalmol; 2004 Nov; 88(11):1429-33. PubMed ID: 15489488
[TBL] [Abstract][Full Text] [Related]
16. Posttranslational regulation of neurofibromin content in melanocytes of neurofibromatosis type 1 patients.
Kaufmann D; Bartelt B; Hoffmeyer S; Müller R
Arch Dermatol Res; 1999 Jun; 291(6):312-7. PubMed ID: 10421056
[TBL] [Abstract][Full Text] [Related]
17. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
[TBL] [Abstract][Full Text] [Related]
18. Nevus anemicus: a distinctive cutaneous finding in neurofibromatosis type 1.
Hernández-Martín A; García-Martínez FJ; Duat A; López-Martín I; Noguera-Morel L; Torrelo A
Pediatr Dermatol; 2015; 32(3):342-7. PubMed ID: 25690591
[TBL] [Abstract][Full Text] [Related]
19. Juvenile xanthogranuloma in neurofibromatosis type 1. Prevalence and possible correlation with lymphoproliferative diseases: experience of a single center and review of the literature.
Miraglia E; Laghi A; Moramarco A; Giustini S
Clin Ter; 2022; 173(4):353-355. PubMed ID: 35857053
[TBL] [Abstract][Full Text] [Related]
20. Analysis of neurofibromatosis 1 (NF1) lesions by body segment.
Palmer C; Szudek J; Joe H; Riccardi VM; Friedman JM
Am J Med Genet A; 2004 Mar; 125A(2):157-61. PubMed ID: 14981716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
